1. Home
  2. EML vs DAWN Comparison

EML vs DAWN Comparison

Compare EML & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern Company (The)

EML

Eastern Company (The)

HOLD

Current Price

$20.52

Market Cap

119.2M

ML Signal

HOLD

Logo Day One Biopharmaceuticals Inc.

DAWN

Day One Biopharmaceuticals Inc.

HOLD

Current Price

$9.37

Market Cap

970.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EML
DAWN
Founded
1858
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.2M
970.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EML
DAWN
Price
$20.52
$9.37
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$26.56
AVG Volume (30 Days)
16.1K
2.9M
Earning Date
11-04-2025
11-04-2025
Dividend Yield
2.15%
N/A
EPS Growth
N/A
N/A
EPS
1.19
N/A
Revenue
$258,121,226.00
$133,672,000.00
Revenue This Year
$1.56
$15.51
Revenue Next Year
$7.00
$49.99
P/E Ratio
$19.83
N/A
Revenue Growth
N/A
31.11
52 Week Low
$18.49
$5.64
52 Week High
$29.55
$13.53

Technical Indicators

Market Signals
Indicator
EML
DAWN
Relative Strength Index (RSI) 50.63 55.87
Support Level $18.96 $8.13
Resistance Level $20.70 $9.82
Average True Range (ATR) 0.64 0.53
MACD 0.07 0.07
Stochastic Oscillator 50.00 54.62

Price Performance

Historical Comparison
EML
DAWN

About EML Eastern Company (The)

The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Share on Social Networks: